A Phase 1 Dose Escalation Trial Of CP-675,206 In Combination With Gemcitabine In Patients With Chemotherapy Naive Metastatic Pancreatic Cancer.

Trial Profile

A Phase 1 Dose Escalation Trial Of CP-675,206 In Combination With Gemcitabine In Patients With Chemotherapy Naive Metastatic Pancreatic Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2014

At a glance

  • Drugs Gemcitabine; Tremelimumab
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Pharmacogenomic
  • Most Recent Events

    • 05 Jun 2012 Company (AstraZeneca) added as reported by ClinicalTrials.gov.
    • 08 Aug 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
    • 08 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top